 |
|
Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis
Ho Soo Chun, A Reum Choe, Minjong Lee, Yuri Cho, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Clin Mol Hepatol. 2021;27(4):535-552. Published online 2021 Jun 16 DOI: https://doi.org/10.3350/cmh.2021.0109
|
|
Citations to this article as recorded by
 Portal Vein Variations, Clinical Correlation, and Embryological Explanation: A Review Article
Gareema Tyagi, Roshan K Jha
Cureus.2023;[Epub] CrossRef Heparins for prevention and treatment of venous thromboembolism in cirrhosis: Research advances
Zhe Li, Wen-Tao Xu, Xiang-Bo Xu, Xing-Shun Qi
World Chinese Journal of Digestology.2022; 30(9): 381. CrossRef Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?
Xiaobing Wang, Liping Chen
Hepatology International.2022; 16(5): 1248. CrossRef Direct oral anticoagulants (DOACs): From the laboratory point of view
Sandra Margetić, Sandra Šupraha Goreta, Ivana Ćelap, Marija Razum
Acta Pharmaceutica.2022; 72(4): 459. CrossRef
|